FDA Grants Breakthrough Device Status to Rhythio Medical’s Injectable Electrode System

Rhythio Medical has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Injectable Electrode System, an innovative technology aimed at providing painless, imperceptible defibrillation and cardiac pacing through a minimally invasive procedure.

Unlike conventional metal leads or coils, the company’s Injectable Electrode Gel serves as the electrode itself. 

This soft, conductive hydrogel can be injected directly into heart tissue, where it forms a stable electrical interface that works seamlessly with existing implantable cardioverter defibrillators (ICDs) and pacemakers. 

The system enables traditional high-voltage shocks to be replaced with gentle, low-intensity therapy designed to enhance patient comfort.

The FDA’s recognition highlights the potential of Rhythio’s solution to redefine cardiac rhythm management and broaden access to life-saving treatments. 

The Breakthrough Devices Program provides priority guidance and review for medical technologies that address serious or life-threatening conditions.

Rhythio Medical is progressing through preclinical development of its Injectable Electrode System in partnership with leading research and clinical institutions and is preparing for first-in-human trials. 

The company’s technology integrates advances in biomaterials and electrophysiology to create a safer, more humane approach to cardiac rhythm therapy.